Buy Provera (Medroxyprogesterone 10mg) Online - Original Upjohn Pfizer Brand Torrent Serum Generic Progestin
Provera (Medroxyprogesterone Acetate 10 mg) represents the foundational synthetic progestin therapy - the reference 17-hydroxyprogesterone derivative established over 65 years for menstrual disorder management, endometrial protection during hormone replacement therapy, endometrial hyperplasia prevention and treatment, and secondary amenorrhea induction. Originally developed by Upjohn Company and FDA-approved as Provera in 1959 for endometriosis, subsequently expanded to comprehensive gynecological indications, medroxyprogesterone acetate (MPA) has over 65 years of continuous clinical use as reference synthetic progestin therapy. Following Upjohn merger with Pharmacia in 2000 and Pfizer acquisition of Pharmacia in 2003, Provera brand rights currently belong to Pfizer maintaining original brand identity internationally. Provera on rxshop.md is available from two quality manufacturers: Torrent Pharmaceuticals and Serum Pharmaceuticals - established Indian pharmaceutical manufacturers providing bioequivalent generic quality.
Medroxyprogesterone acetate (MPA) is a 17-hydroxyprogesterone derivative synthetic progestin - specifically 17-alpha-acetoxy-6-alpha-methylprogesterone. This structural modification provides potent progestogenic activity with distinctive pharmacological profile distinguishing MPA from other synthetic progestins. MPA acts as selective progesterone receptor agonist with additional weak glucocorticoid activity and modest androgenic effects unlike newer selective progestins (dydrogesterone, drospirenone). MPA provides effective endometrial modification, ovulation suppression at higher doses, and comprehensive progestogenic effects across target tissues.
Provera addresses comprehensive gynecological indications including secondary amenorrhea, dysfunctional uterine bleeding, endometriosis, endometrial hyperplasia prevention and treatment, and serves as the progestogen component in combined hormone replacement therapy for postmenopausal women with intact uterus. Provera at 10 mg strength provides standard dosing across multiple indications from cyclic cycle induction through continuous HRT combination therapy. Extensive clinical experience over 65 years supports evidence-based prescribing across the postmenopausal and reproductive age populations.
Provera is available in three pack sizes - 60, 90, and 120 tablets - accommodating monthly through 4-month therapy durations. The 120-tablet pack is the bestseller reflecting extended HRT protocols and long-term cyclical use. Provera was the specific progestin studied in the landmark Women Health Initiative (WHI) 2002 combined estrogen-progestin arm that terminated early due to safety concerns, contributing to modern HRT prescribing principles. Contraindicated in pregnancy, undiagnosed vaginal bleeding, known breast cancer, active thromboembolic disease, and severe liver dysfunction.
Free prescription
Discrete packaging
Have questions?
Quality Assurance
- Dysfunctional Uterine Bleeding: Abnormal heavy or irregular menstrual bleeding without underlying organic pelvic pathology responding to progestin therapy;
- Endometrial Hyperplasia Treatment: Treatment of endometrial hyperplasia inducing endometrial regression through progestin action on uterine lining;
- Endometrial Hyperplasia Prevention: Prevention of endometrial hyperplasia during postmenopausal estrogen replacement therapy in women with intact uterus;
- HRT Progestin Component: Progestogen component in combined hormone replacement therapy providing endometrial protection during estrogen therapy;
- Endometriosis: Painful gynecological condition where endometrial tissue grows outside the uterine cavity responding to progestin suppression;
- Endometrial Cancer Palliative: Palliative therapy for hormone receptor positive advanced endometrial adenocarcinoma in selected patients;
- Irregular Menstrual Cycles: Menstruation at unpredictable intervals due to hormonal imbalance affecting normal ovulation cycles;
- Oligomenorrhea: Infrequent menstruation with cycles longer than 35 days indicating ovulatory dysfunction and hormonal imbalance;
- Anovulatory Bleeding: Menstrual bleeding disorders from anovulation responding to cyclic progestin regulation therapy;
- Premenstrual Syndrome Selected Use: Selected use for premenstrual syndrome with elevated progestin deficiency contributing to cyclic symptoms;
- Progesterone Withdrawal Test: Diagnostic use to establish endometrial estrogen exposure and rule out primary anovulation causes;
- Menstrual Disorders: Broad category of cycle irregularities including timing frequency and flow abnormalities responding to progestin regulation;
- Perimenopausal Bleeding Management: Regulation of erratic bleeding during menopausal transition through cyclic progestin administration;
- Continuous Combined HRT: Progestogen for continuous combined hormone therapy providing endometrial protection without withdrawal bleeding;
- Cyclic Combined HRT: Progestogen for cyclic combined hormone therapy producing predictable monthly withdrawal bleeding pattern;
- Renal Cell Carcinoma Palliative: Historical palliative use for advanced renal cell carcinoma in selected patients;
- Endometrial Protection HRT: Prevention of endometrial hyperplasia and cancer from unopposed estrogen exposure in HRT users;
- Withdrawal Bleeding Induction: Induced withdrawal bleeding for cycle regulation or diagnostic purposes in amenorrhea evaluation;
- Progestin Deficiency States: Clinical conditions of insufficient natural progesterone production requiring progestogen supplementation therapy.
- Regulates Menstrual Cycles: Establishment of predictable regular menstrual cycles through cyclic progestogen administration therapy;
- Controls Dysfunctional Uterine Bleeding: Effective bleeding control and cycle regulation in dysfunctional uterine bleeding cases;
- Treats Endometrial Hyperplasia: Endometrial regression in simple hyperplasia without atypia through progestin action on uterine lining;
- Prevents Endometrial Cancer HRT: Substantial reduction in endometrial cancer risk during postmenopausal estrogen therapy protecting uterine lining;
- Improves Endometriosis Pain: Reduction in pelvic pain dysmenorrhea and dyspareunia from endometriosis through progestin suppression;
- Enables Combined HRT: Progestogen component makes combined HRT possible in women with intact uterus preventing endometrial hyperplasia;
- Reduces Heavy Bleeding: Substantial reduction in menstrual flow volume decreasing iron deficiency anemia risk from heavy bleeding;
- Restores Ovulatory Cycles: Reestablishment of predictable withdrawal bleeding patterns in anovulatory patients through cyclic therapy;
- Well Established Safety Data: Over 65 years of continuous clinical use with extensive safety and efficacy documentation;
- Oral Tablet Administration: Simple oral administration avoiding injections or complex administration procedures for progestogen therapy;
- Flexible Dosing Protocols: Standard 10 mg strength enables cyclic short courses through continuous long-term HRT protocols;
- Cost Effective Progestin: More affordable than newer synthetic progestins for extended therapy and HRT applications;
- Two Manufacturer Options: Torrent and Serum manufacturing provides bioequivalent generic options with quality standards;
- Upjohn Original Brand Heritage: FDA-approved 1959 with over 65 years continuous clinical use worldwide;
- Comprehensive Gynecological Coverage: Multiple gynecological indications from cycle regulation through HRT combination from single medication;
- Diagnostic Utility: Progesterone withdrawal test provides valuable diagnostic information in amenorrhea evaluation;
- Extended Pack Size Options: 60 to 120 tablet packs accommodate short courses through long-term HRT protocol supplies;
- Amenorrhea Cycle Induction: Effective withdrawal bleeding induction confirming endometrial estrogen exposure diagnostically;
- Better Quality of Life: Regulated menstruation endometriosis pain relief and HRT enabling substantially improve quality of life outcomes.
Generic Provera (Medroxyprogesterone 10 mg) Medication guide:
Provera (Medroxyprogesterone Acetate 10 mg) represents the foundational synthetic progestin therapy - the reference 17-hydroxyprogesterone derivative established over 65 years for menstrual disorder management, endometrial protection during hormone replacement therapy, endometrial hyperplasia prevention and treatment, and secondary amenorrhea induction. Originally developed by Upjohn Company and FDA-approved as Provera in 1959, medroxyprogesterone acetate (MPA) has over 65 years of continuous clinical use. Following Upjohn merger with Pharmacia in 2000 and Pfizer acquisition of Pharmacia in 2003, Provera brand rights currently belong to Pfizer. Provera on rxshop.md is manufactured by Torrent Pharmaceuticals and Serum Pharmaceuticals with quality manufacturing standards. Approved for secondary amenorrhea, dysfunctional uterine bleeding, endometriosis, endometrial hyperplasia treatment and prevention, and combined HRT progestogen component. This comprehensive medication guide covers synthetic progestin pharmacology, 17-hydroxyprogesterone derivative mechanism, all approved indications, dosing protocols per indication, WHI 2002 combined arm data, comprehensive contraindications, drug interactions, and long-term therapy considerations.
💊 Introduction to Provera
Provera is a prescription oral medication containing medroxyprogesterone acetate (MPA) 10 mg as its active ingredient in tablet form. Medroxyprogesterone acetate is a synthetic 17-hydroxyprogesterone derivative progestin - specifically 17-alpha-acetoxy-6-alpha-methylprogesterone. This structural modification provides potent progestogenic activity distinguishing MPA from other synthetic progestin classes including 19-nortestosterone derivatives (norethindrone, levonorgestrel) and retroprogesterone derivatives (dydrogesterone).
Provera was originally developed by Upjohn Company and received FDA approval in 1959 initially for endometriosis treatment. Subsequent FDA approvals expanded indications to include secondary amenorrhea, dysfunctional uterine bleeding, endometrial hyperplasia, and combined hormone replacement therapy progestogen component. The Provera brand identity transitioned through Upjohn merger with Pharmacia in 2000 creating Pharmacia and Upjohn, and subsequently Pfizer acquisition of Pharmacia in 2003 in a 60 billion dollar merger. Pfizer currently maintains Provera brand rights globally.
The Provera brand available on rxshop.md is manufactured by two Indian pharmaceutical companies: Torrent Pharmaceuticals - established Indian pharmaceutical manufacturer founded 1959 with global operations and WHO-GMP certified manufacturing facilities, and Serum Pharmaceuticals - established Indian pharmaceutical manufacturer with generic portfolio focused on reproductive medicine and endocrinology. Both manufacturers produce bioequivalent generic medroxyprogesterone acetate under quality manufacturing standards.
Medroxyprogesterone acetate has a distinctive pharmacological profile that distinguishes it from other synthetic progestins. Beyond primary progestogenic activity, MPA exhibits weak glucocorticoid activity and modest androgenic effects. These secondary hormonal activities differ from newer selective progestins (dydrogesterone, drospirenone) that provide more selective progestogenic effects without off-target hormonal activities. The MPA pharmacological profile has implications for tolerability, side effects, and clinical use decisions.
Provera served as the specific synthetic progestin studied in the landmark Women Health Initiative (WHI) 2002 combined estrogen-progestin arm. WHI results using conjugated equine estrogens (Premarin) plus medroxyprogesterone acetate (Provera) demonstrated cardiovascular, thromboembolic, and breast cancer risks that fundamentally transformed HRT prescribing practices worldwide. Modern hormone therapy prescribing incorporates WHI findings emphasizing appropriate patient selection, lowest effective dose, and shortest effective duration principles.
Provera is available on rxshop.md in three pack sizes - 60, 90, and 120 tablets. The 120-tablet pack is the bestseller reflecting extended HRT protocols and long-term cyclical use for menstrual disorders and endometriosis management.
🏭 Torrent and Serum Manufacturers
Torrent Pharmaceuticals Credentials
Torrent Pharmaceuticals credentials:
- Founded 1959 in Ahmedabad India - over 65 years pharmaceutical heritage
- Global operations in over 40 countries worldwide
- WHO-GMP certification - highest quality manufacturing standards
- US FDA-inspected facilities serving American regulatory market
- EU-GMP certification serving European market
- UK MHRA approval for United Kingdom distribution
- Multiple manufacturing facilities across India
- Established womens health portfolio including hormonal therapy products
- Comprehensive gynecology product line
Serum Pharmaceuticals Credentials
Serum Pharmaceuticals credentials:
- Established Indian pharmaceutical manufacturer with generic portfolio
- Focus on reproductive medicine and endocrinology therapeutic areas
- Quality manufacturing standards ensuring bioequivalent generic quality
- Cost-effective manufacturing enabling accessible progestin therapy pricing
- Regional and international distribution
- Comprehensive gynecology product line including hormone therapy medications
📜 Upjohn and Pfizer Brand Heritage
Historical Timeline
| Year | Development Milestone |
|---|---|
| 1950s | Upjohn Company research on 17-hydroxyprogesterone derivatives |
| 1957 | Medroxyprogesterone acetate first synthesized by Upjohn scientists |
| 1959 | FDA approval of Provera by Upjohn for endometriosis |
| 1960s | Expanded indications to secondary amenorrhea and dysfunctional uterine bleeding |
| 1970s-1980s | Establishment as standard progestogen for combined HRT with estrogen therapy |
| 1992 | Depo-Provera (150 mg injectable MPA) approved for contraception |
| 1994 | Prempro (Premarin + MPA combination tablet) approved for HRT |
| 2000 | Upjohn merged with Pharmacia forming Pharmacia and Upjohn |
| 2002 | WHI combined arm using Premarin plus MPA stopped early - landmark HRT results |
| 2003 | Pfizer acquired Pharmacia in 60 billion dollar merger - obtained Provera brand rights |
| Present Day | Over 65 years continuous clinical use - reference synthetic progestin worldwide |
Provera Significance in Gynecological Medicine
Provera introduction in 1959 represented a significant advance in gynecological medicine providing the first widely used oral synthetic progestin for endometriosis, menstrual disorders, and hormone therapy. Over 65 years of continuous clinical use has generated extensive safety and efficacy data supporting evidence-based prescribing. Provera was pivotal in enabling widespread combined HRT use during the 1980s-1990s. The WHI 2002 findings specifically involving MPA fundamentally shaped modern HRT prescribing including individualized risk-benefit assessment and shortest effective duration principles.
🧬 Understanding Progestogens Class
Progestogen Categories
Progestogen class categories:
- Natural progesterone: Micronized progesterone identical to endogenous hormone
- Progesterone derivatives: Dydrogesterone (retroprogesterone), medroxyprogesterone acetate
- 17-hydroxyprogesterone derivatives: MPA (Provera), megestrol acetate - potent progestogenic activity
- 19-nortestosterone derivatives: Norethindrone, levonorgestrel, gestodene - typically androgenic
- Spirolactone derivatives: Drospirenone with anti-mineralocorticoid activity
- 19-norprogesterone derivatives: Nomegestrol acetate, trimegestone
MPA Position Within Progestogen Class
MPA occupies a distinctive position as the reference 17-hydroxyprogesterone derivative synthetic progestin. Advantages include potent progestogenic activity, oral bioavailability enabling convenient tablet therapy, well-established safety and efficacy database over 65 years, cost-effectiveness compared to newer progestins, and comprehensive indication coverage across gynecological conditions. Distinctive characteristics compared to newer selective progestins include weak glucocorticoid activity and modest androgenic effects that may contribute to differences in cardiovascular signals observed in WHI trial versus other progestogens.
🧪 Chemistry of Medroxyprogesterone Acetate
Chemical Structure
Medroxyprogesterone acetate has the chemical formula C24H34O4 with molecular weight approximately 386.5 g/mol. Chemically, MPA is 17-alpha-acetoxy-6-alpha-methylprogesterone - a synthetic steroid with the pregnane skeleton featuring 6-alpha-methyl substitution and 17-alpha-acetoxy modification of the progesterone structure. This dual structural modification distinguishes MPA from natural progesterone providing enhanced oral bioavailability and potency.
Structural Features
MPA structural features:
- Pregnane backbone - characteristic 21-carbon steroid nucleus
- 6-alpha-methyl group - key structural feature enhancing oral bioavailability
- 17-alpha-acetoxy group - esterified hydroxyl providing prolonged activity
- 3-keto-4-ene structure - progestogenic activity foundation
- 20-keto group - progesterone-like C20 configuration
- Distinct from 19-nortestosterone derivatives - lacks androgenic 19-nor structure
- Distinct from dydrogesterone - lacks retro-configuration
🔬 Mechanism of Action
Cellular Mechanism
MPA mechanism at cellular level:
- Cell membrane diffusion: MPA passively diffuses across cell membranes due to lipophilic structure
- Progesterone receptor binding: Binds progesterone receptors (PR-A and PR-B) with high affinity
- Receptor activation: Ligand-receptor complex undergoes conformational change
- Nuclear translocation: Activated receptor-ligand complex moves into cell nucleus
- DNA binding: Binds progesterone response elements on target gene promoters
- Gene transcription: Regulates transcription of progesterone-responsive genes
- Protein synthesis: Modulates production of proteins mediating progesterone effects
- Secondary receptor activity: Additional weak binding to glucocorticoid and androgen receptors
Multi-Receptor Activity Profile
- Progestogenic activity: Primary target - strong progesterone receptor agonism
- Weak glucocorticoid activity: Some binding to glucocorticoid receptor at higher doses
- Modest androgenic activity: Some testosterone-like effects unlike dydrogesterone
- No estrogenic activity: Does not bind estrogen receptors
- No anti-mineralocorticoid activity: Unlike drospirenone
Endometrial Effects
MPA endometrial effects:
- Secretory transformation: Converts proliferative endometrium to secretory state
- Endometrial hyperplasia prevention: Opposes estrogen-stimulated proliferation during HRT
- Withdrawal bleeding: Induces controlled bleeding when discontinued cyclically
- Endometrial hyperplasia regression: Progestin therapy induces endometrial regression
- Endometriosis suppression: Reduces ectopic endometrial tissue activity
- Endometrial stabilization: Controls dysfunctional uterine bleeding through endometrial regulation
🔬 Pharmacokinetic Profile
| Parameter | Value | Clinical Significance |
|---|---|---|
| Oral absorption | Rapid and reliable | Predictable oral therapy |
| Oral bioavailability | Good | Enhanced by 6-alpha-methyl and 17-alpha-acetoxy modifications |
| Time to peak (Tmax) | 2-7 hours | Delayed absorption timing |
| Half-life | Approximately 30 hours | Long half-life supports once daily dosing |
| Protein binding | Approximately 90 percent | Highly protein bound to albumin |
| Metabolism | Hepatic CYP3A4 | Converted to hydroxylated metabolites |
| Elimination | Fecal and renal | Approximately 74 percent fecal excretion |
| Steady state | Within 1 week | Rapid therapeutic effect assessment |
| Onset of clinical effect | Days to weeks | Progressive symptom improvement with continued therapy |
| Withdrawal bleeding timing | 3-7 days after last dose | Predictable cyclic bleeding pattern |
🧠 Understanding Progesterone Physiology
Natural Progesterone Role
Progesterone physiology overview:
- Produced primarily by corpus luteum after ovulation
- Placental production during pregnancy after weeks 8-10
- Adrenal cortex minor production as steroid precursor
- Blood level ranges: Under 1 ng/mL follicular; 5-25 ng/mL luteal; increasing during pregnancy
- Primary role: Endometrial preparation and pregnancy maintenance
- Reproductive functions: Menstrual cycle regulation, ovulation preparation, embryo implantation
- Non-reproductive roles: Neurosteroid activity, immune modulation, thermogenic effect
Menstrual Cycle Progesterone Role
During natural menstrual cycle, progesterone rises during luteal phase (days 14-28) from corpus luteum production. This causes secretory endometrial transformation preparing for potential implantation. Without pregnancy, corpus luteum regresses causing progesterone withdrawal that triggers menstruation. In anovulatory cycles, absence of ovulation means no corpus luteum forms and progesterone remains low - endometrium remains proliferative under continued estrogen exposure without secretory transformation. This can lead to endometrial hyperplasia and cancer risk with prolonged unopposed estrogen exposure.
🎯 FDA Approved Indications
- Secondary Amenorrhea
- Absence of menstruation for three or more months in previously menstruating reproductive age women. MPA induces withdrawal bleeding confirming endometrial estrogen exposure. Standard dosing: 5-10 mg daily for 5-10 days.
- Dysfunctional Uterine Bleeding
- Abnormal heavy or irregular menstrual bleeding without underlying organic pelvic pathology. MPA stabilizes endometrium and regulates bleeding pattern. Standard dosing: 5-10 mg daily for 5-10 days per cycle for regulation.
- Endometrial Hyperplasia Treatment
- Simple endometrial hyperplasia without atypia treated with progestin therapy inducing endometrial regression. Standard dosing: 10 mg daily continuously for 3-6 months with follow-up endometrial biopsy.
- HRT Progestogen Component
- Progestogen component in combined hormone replacement therapy for postmenopausal women with intact uterus to prevent endometrial hyperplasia from unopposed estrogen. Standard dosing: 2.5 mg daily continuous or 5-10 mg cyclic for 12-14 days per month.
- Endometriosis
- Painful gynecological condition where endometrial tissue grows outside uterine cavity. MPA provides continuous progestin suppression reducing ectopic endometrial activity. Standard dosing: 10-30 mg daily continuously for 6+ months.
- Palliative Treatment of Metastatic Endometrial Cancer
- Palliative therapy for hormone receptor positive advanced endometrial adenocarcinoma. Specialist oncology use in specific clinical circumstances. Higher doses typically used.
- Palliative Treatment of Renal Cell Carcinoma
- Historical palliative use for advanced renal cell carcinoma. Modern targeted therapies typically preferred. Higher doses required.
👤 Ideal Patient Selection
Provera most appropriate for:
- Women with secondary amenorrhea requiring cycle induction
- Women with dysfunctional uterine bleeding requiring endometrial stabilization
- Women with endometrial hyperplasia requiring progestin regression therapy
- Postmenopausal women on estrogen therapy with intact uterus requiring endometrial protection
- Endometriosis patients requiring continuous progestin suppression
- Women with irregular menstrual cycles requiring cyclic progestin regulation
- Women undergoing progesterone withdrawal test for amenorrhea evaluation
- Patients preferring cost-effective established progestin over newer selective agents
- Patients accepting side effect profile with weak glucocorticoid and androgenic effects
- Patients without contraindications to progestin therapy
- Selected metastatic endometrial cancer patients requiring palliative therapy
- Patients accepting gynecology specialist supervision
🚫 Contraindications
Absolute Contraindications
- Pregnancy or suspected pregnancy
- Undiagnosed abnormal vaginal bleeding - requires diagnostic evaluation first
- Known or suspected breast cancer
- Known or suspected estrogen-dependent malignancy
- Active thromboembolic disorders - DVT, PE, thromboembolism
- History of thromboembolic disorders
- Missed abortion - non-viable pregnancy with retained products
- Severe liver dysfunction or liver disease
- Hypersensitivity to MPA or tablet excipients
- Cerebrovascular disease active or history
Precautions
Use with caution in:
- Depression history: Monitor mood during therapy
- Diabetes mellitus: Monitor glucose control - glucocorticoid effect
- Hypertension: Monitor blood pressure
- Migraine history: Rare exacerbation reports
- Cardiovascular disease: WHI signals in combined arm
- Breast disease history: Standard breast health monitoring
- Renal impairment: Fluid retention risk
- Long-term use: Reassessment for lowest effective dose
📊 WHI Combined Arm Data
WHI Combined Arm Trial
WHI combined arm design and results (2002):
- Approximately 16,608 postmenopausal women ages 50-79
- Combined therapy tested: Premarin (0.625 mg CEE) + Provera (2.5 mg MPA) vs placebo
- Trial stopped early at 5.2 years due to breast cancer signal
- Increased invasive breast cancer: 26 percent increase (statistically significant)
- Increased coronary heart disease: 29 percent increase
- Increased stroke: 41 percent increase
- Increased pulmonary embolism: 113 percent increase
- Reduced hip fractures: 34 percent reduction
- Reduced colorectal cancer: 37 percent reduction
- Overall harm exceeded benefit in trial population
WHI Implications for MPA Use
WHI results specifically involving MPA in combined HRT led to significant reassessment of continuous combined estrogen-progestin therapy. Modern prescribing considers WHI findings emphasizing individualized risk-benefit assessment. Some analyses suggest MPA specifically may contribute to cardiovascular signals more than other progestogens (dydrogesterone, natural progesterone) that appear more cardiovascular-neutral. This has contributed to preferential use of newer selective progestins in HRT combination therapy where available and appropriate.
💉 Comprehensive Dosing Protocols
Indication-Specific Dosing
| Indication | Standard Dose | Duration |
|---|---|---|
| Secondary Amenorrhea | 5-10 mg daily | 5-10 days per cycle |
| Dysfunctional Uterine Bleeding | 5-10 mg daily | 5-10 days per cycle for regulation |
| Endometrial Hyperplasia Treatment | 10 mg daily | Continuously for 3-6 months with biopsy follow-up |
| HRT Continuous Combination | 2.5 mg daily | Continuous with continuous estrogen |
| HRT Cyclic Combination | 5-10 mg daily | 12-14 days per month with cyclic estrogen |
| Endometriosis | 10-30 mg daily | Continuously for 6+ months |
| Endometrial Cancer Palliative | 200-400 mg daily (higher doses) | Specialist oncology guidance |
| Renal Cell Carcinoma Palliative | 100-500 mg daily (higher doses) | Specialist oncology guidance |
Administration Guidelines
- Take tablets whole with water
- May be taken with or without food
- Take at approximately the same time each day
- Do not double dose if missed - resume next scheduled dose
- Complete prescribed cyclic protocol before pill-free interval
- Continuous therapy takes daily without breaks
- Cyclic therapy follows specific cycle day schedule per prescription
- Report unexpected bleeding patterns during therapy
- Maintain regular gynecology follow-up appointments
- Regular breast cancer screening during long-term therapy
🔬 Progesterone Withdrawal Test
Progesterone withdrawal test protocol:
- Indication: Evaluation of secondary amenorrhea to establish endometrial estrogen exposure
- Standard dosing: MPA 10 mg daily for 5-10 days
- Interpretation: Withdrawal bleeding 3-7 days after last dose confirms adequate endogenous estrogen
- Positive result: Withdrawal bleeding indicates ovulation dysfunction with adequate estrogen (PCOS, hypothalamic dysfunction)
- Negative result: No withdrawal bleeding suggests inadequate estrogen (POI, primary ovarian failure) or anatomic issue
- Diagnostic value: Guides further workup for amenorrhea causes
- Traditional gynecologic evaluation tool - modern practice uses hormonal panels more commonly
📊 Clinical Effectiveness Data
| Outcome | Response Data |
|---|---|
| Secondary amenorrhea cycle induction | Effective withdrawal bleeding in majority with adequate estrogen |
| Dysfunctional uterine bleeding control | Substantial cycle regulation in majority of patients |
| Endometrial hyperplasia regression | Effective regression in simple hyperplasia without atypia |
| HRT endometrial protection | Effective endometrial protection during estrogen therapy |
| Endometriosis pain relief | Substantial reduction in pelvic pain and dysmenorrhea |
| Menstrual cycle regulation | Predictable withdrawal bleeding in majority |
| Time to symptom improvement | Days to weeks for progressive improvement |
| Long-term safety data | Over 65 years continuous clinical use with established profile |
⚠️ Side Effects
Common Side Effects
- Breakthrough bleeding: Common - typically resolves with continued therapy
- Amenorrhea: May develop with continuous therapy
- Breast tenderness: Common - typically transient
- Weight changes: Variable - typically modest weight gain
- Bloating and fluid retention: Common - glucocorticoid effect
- Headache: Common
- Nausea: Occasional
- Mood changes: Variable - depression concerns in some patients
- Fatigue: Occasional
- Dizziness: Occasional
- Insomnia: Uncommon
- Acne: Uncommon - modest androgenic effect
- Hirsutism: Rare - modest androgenic effect
- Skin rash: Uncommon
- Abdominal cramping: Occasional
- Decreased libido: Occasional
Serious Adverse Events
Seek immediate medical attention for:
- Signs of DVT: Leg pain swelling redness warmth
- Signs of PE: Chest pain shortness of breath rapid breathing
- Signs of stroke: Sudden numbness weakness speech difficulty vision changes
- Sudden severe headache with neurological symptoms
- Vision changes or loss
- Signs of severe allergic reaction: Angioedema, difficulty breathing
- Signs of liver dysfunction: Jaundice dark urine severe abdominal pain
- Severe depression or suicidal thoughts
- Breast lump or breast changes
- Unusual persistent vaginal bleeding
- Suspected pregnancy
🔄 Drug Interactions
| Drug/Substance | Interaction |
|---|---|
| Rifampicin | CYP3A4 induction reduces MPA effectiveness |
| Phenytoin, carbamazepine, phenobarbital | Enzyme induction reduces MPA levels |
| St Johns Wort | Herbal enzyme induction reduces MPA levels |
| Ketoconazole, itraconazole | CYP3A4 inhibition may increase MPA levels |
| Aminoglutethimide | Substantially reduces MPA effectiveness |
| Estrogens | Standard combination for HRT - not adverse interaction |
| Corticosteroids | Additive glucocorticoid effects with high MPA doses |
| Insulin and diabetes medications | Monitor glucose - glucocorticoid effect at high MPA doses |
| Warfarin | Monitor INR periodically |
| Bromocriptine, cabergoline | MPA may reduce dopamine agonist effectiveness |
| Smoking | Substantially increases cardiovascular and thromboembolic risks |
🔄 MPA vs Dydrogesterone Comparison
| Feature | MPA (Provera) | Dydrogesterone (Duphaston) |
|---|---|---|
| Class | 17-hydroxyprogesterone derivative | Retroprogesterone stereoisomer |
| Progestogenic activity | Strong | Strong selective |
| Glucocorticoid activity | Weak activity present | None |
| Androgenic activity | Modest activity present | None |
| Cardiovascular signal | WHI concerns in combined arm | Appears cardiovascular-neutral |
| Pregnancy safety | Not indicated for pregnancy support | Approved for pregnancy support |
| Cost | More affordable | Moderate cost |
| FDA approval | Yes - since 1959 | Not FDA approved (US market withdrawal 2008) |
🛡️ Special Populations
- Reproductive Age Women
- Primary target population for menstrual disorders, endometriosis, and dysfunctional uterine bleeding indications. Comprehensive gynecological evaluation before therapy.
- Postmenopausal Women with Intact Uterus
- Standard progestogen for combined HRT providing endometrial protection during estrogen therapy. Regular breast cancer screening and cardiovascular assessment.
- Endometriosis Patients
- Continuous higher-dose therapy for pain management. Long-term therapy typically required. Multidisciplinary approach with gynecology specialist.
- Endometrial Hyperplasia Patients
- Continuous therapy for 3-6 months with follow-up endometrial biopsy documenting regression. Long-term surveillance for recurrence.
- Amenorrhea Patients
- Cyclic short-course therapy for withdrawal bleeding induction. Progesterone withdrawal test diagnostic value.
- Pregnant Women
- Contraindicated. Not indicated during pregnancy. Discontinue immediately if pregnancy suspected. Not for pregnancy support (unlike dydrogesterone).
- Depression History
- Monitor mood carefully during therapy. Depression concerns reported with MPA use. Consider mental health support.
- Diabetic Patients
- Monitor glucose control periodically. Weak glucocorticoid activity may affect insulin sensitivity in some patients particularly at higher doses.
- Cardiovascular Disease Patients
- Enhanced monitoring given WHI combined arm cardiovascular signals. Individualized risk-benefit assessment. Alternative progestins may be preferred.
- Thromboembolism History Patients
- Contraindicated. Active or history of VTE excludes MPA therapy. Alternative therapies needed.
- Breast Cancer History
- Contraindicated. Known or suspected breast cancer excludes MPA. Non-hormonal alternatives preferred.
- Hepatic Impairment
- Severe hepatic impairment contraindicated. Mild-moderate impairment use with caution and monitor liver function.
📦 Storage and Handling
- Store at room temperature 15-30°C (59-86°F)
- Protect from light and moisture
- Keep tablets in original packaging
- Keep out of reach of children and pets
- Do not use past expiration date
- Do not share medication with others
- Return unused medication to pharmacy for proper disposal
- Store in dry area - avoid humid bathrooms
👨⚕️ When to Contact Your Doctor
- Signs of DVT: leg pain swelling redness warmth
- Signs of PE: chest pain shortness of breath rapid breathing
- Signs of stroke: sudden numbness weakness speech difficulty
- Sudden severe headache with neurological symptoms
- Vision changes or loss
- Breast lump or breast changes
- Unusual persistent vaginal bleeding
- Signs of liver dysfunction: jaundice dark urine
- Severe depression or mood changes
- Signs of severe allergic reaction
- Suspected pregnancy
- Time for scheduled monitoring appointments
- Time for annual breast cancer screening
- Time for cardiovascular assessment
- Consideration of dose adjustment or discontinuation
- Starting new medications potentially interacting
- Persistent side effects affecting daily activities
- Endometrial biopsy follow-up for hyperplasia treatment
🌟 Key Takeaways
Essential points about Provera therapy:
- Provera is Torrent and Serum generic medroxyprogesterone acetate 10 mg tablets
- Original Upjohn brand FDA-approved 1959 - over 65 years continuous clinical use
- Ownership timeline: Upjohn → Pharmacia 2000 → Pfizer 2003
- 17-hydroxyprogesterone derivative synthetic progestin
- 17-alpha-acetoxy-6-alpha-methylprogesterone chemistry
- Distinct from dydrogesterone and 19-nortestosterone progestins
- Progestogenic activity primary with weak glucocorticoid and modest androgenic effects
- Approved for secondary amenorrhea, dysfunctional uterine bleeding, endometrial hyperplasia
- Approved for endometriosis and HRT combination progestogen component
- Standard dosing 5-10 mg for menstrual disorders, 2.5 mg for continuous HRT, 10-30 mg for endometriosis
- Take with or without food same time daily
- Central to WHI 2002 combined arm - increased breast cancer 26%, CHD 29%, stroke 41%
- WHI reduced hip fractures 34% and colorectal cancer 37% (combined arm)
- Traditional progesterone withdrawal test for amenorrhea evaluation
- Contraindicated in pregnancy, undiagnosed bleeding, breast cancer, VTE history, severe liver disease
- Modern HRT prescribing considers WHI findings favoring newer selective progestins where appropriate
- Regular breast cancer screening and cardiovascular assessment mandatory during long-term therapy
- Two manufacturer options: Torrent and Serum providing bioequivalent generic quality
- Available in 3 pack sizes (60, 90, 120 tablets) accommodating different therapy durations
- 120-tablet pack bestseller reflecting extended HRT and endometriosis protocols
- Report thromboembolic symptoms, breast changes, or unusual bleeding immediately
Important Medical Disclaimer: This medication guide provides general information about Provera (Torrent and Serum generic medroxyprogesterone acetate 10 mg tablets) and does not constitute individualized medical advice. Every patient situation is unique and requires evaluation by a gynecologist, endocrinologist, or qualified healthcare provider before starting progestin therapy. Provera requires comprehensive gynecological workup to establish diagnosis and appropriate indication before therapy initiation. Pregnancy must be excluded before initiating therapy. Undiagnosed abnormal vaginal bleeding requires diagnostic evaluation (endometrial biopsy, transvaginal ultrasound) before progestin therapy. CRITICAL SAFETY: Contraindicated in pregnancy, undiagnosed abnormal vaginal bleeding, known or suspected breast cancer or estrogen-dependent malignancy, active or history of thromboembolic disorders (DVT, PE), missed abortion, severe liver dysfunction, and hypersensitivity. WHI trial 2002 combined arm using MPA plus Premarin demonstrated increased breast cancer, cardiovascular events, stroke, and thromboembolic events risks - these findings shape modern HRT prescribing including individualized risk-benefit assessment, appropriate patient selection, lowest effective dose, and shortest effective duration principles. Regular breast cancer screening (mammography), pelvic examination, blood pressure monitoring, and cardiovascular assessment mandatory during long-term therapy. Weak glucocorticoid activity of MPA may affect glucose control in diabetic patients particularly at higher doses. Modest androgenic activity may contribute to acne or hirsutism in some patients. Endometrial hyperplasia treatment requires follow-up endometrial biopsy documenting regression. Endometriosis therapy typically requires long-term treatment with multidisciplinary specialist coordination. Report symptoms of DVT (leg pain, swelling), PE (chest pain, shortness of breath), stroke (numbness, weakness), breast changes, unusual vaginal bleeding, severe depression, or signs of liver dysfunction immediately. If you experience concerning symptoms contact your healthcare provider promptly. The information provided here should complement but never replace direct professional medical guidance from your gynecologist or endocrinologist.
Provera — Frequently Asked Questions
-
What is Provera (Medroxyprogesterone) used for?
Provera is a synthetic form of progesterone, a female hormone. It's used to treat conditions such as absent or irregular menstrual periods, or abnormal uterine bleeding. In combination with estrogen, it can also be part of hormone replacement therapy to relieve menopause symptoms. -
How does Provera work?
It works by mimicking the effects of natural progesterone, which helps regulate the menstrual cycle and maintain the lining of the uterus. This can correct hormonal imbalances and treat related symptoms. -
What are the side effects of taking Provera?
Common side effects include headaches, breast tenderness, mood swings, bloating, and spotting between periods. Some may experience more severe side effects like jaundice, migraines, or blood clots. -
How should I take Provera?
Provera should be taken exactly as prescribed by your healthcare provider. The dosage can vary based on the condition being treated. It's important not to miss doses and to take the medication at the same time each day. -
Can I take Provera if I am pregnant?
Provera should not be taken if you are pregnant. If you become pregnant while taking Provera, you should stop taking it immediately and contact your healthcare provider. -
Is it safe to take Provera while breastfeeding?
Medroxyprogesterone can pass into breast milk and may harm a nursing baby. Discuss with your healthcare provider whether you should use this medication while breastfeeding. -
Can Provera affect my fertility?
Provera may delay returning to fertility after stopping the medication. However, it is not a long-term method of contraception, and normal fertility is usually restored after ceasing treatment.
See all Provera questions (32)
More Women's Health Medications
